Libervant (Diazepam) Patent Expiration, LOE Window & CMS Spending

Libervant (Diazepam) by Aquestive: Off-Patent Genericized (AB Competition), 11 AB generics, $134K 2024 CMS Part D & Medicaid spend, and $690 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAquestive
FDA Application & PathwayN212641 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors11
2024 CMS Total Public Spend$134K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$134K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($690 intro WAC)